Spiera, Robert F

selected publications

COVID-19 vaccinations and infections among individuals with systemic sclerosis: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. Seminars in arthritis and rheumatism. 2024 Academic Article GET IT
Times cited: 1
Advances in the treatment of polymyalgia rheumatica and giant cell arteritis. Nature reviews. Rheumatology. 2024 Academic Article GET IT
Systemic sclerosis in individuals with exposure to World Trade Center ground-zero rescue/recovery efforts: A case series. The Journal of rheumatology. 2024 Academic Article GET IT
A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis. Arthritis research & therapy. 2023 Academic Article GET IT
Times cited: 7
Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper. The New England journal of medicine. 2023 Academic Article GET IT
Times cited: 12
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis. Arthritis & rheumatology (Hoboken, N.J.). 2023 Academic Article GET IT
Times cited: 1
Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trial. Rheumatology (Oxford, England). 2023 Academic Article GET IT
Times cited: 17
Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial. Annals of the rheumatic diseases. 2023 Academic Article GET IT
Times cited: 47
Autoreactive Plasmablasts After B Cell Depletion With Rituximab and Relapses in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis & rheumatology (Hoboken, N.J.). 2023 Academic Article GET IT
Times cited: 7
Activation of a Latent Epitope Causing Differential Binding of Antineutrophil Cytoplasmic Antibodies to Proteinase 3. Arthritis & rheumatology (Hoboken, N.J.). 2023 Academic Article GET IT
Times cited: 1
Risk of relapse of ANCA-associated vasculitis among patients homozygous for the proteinase 3 gene Val119Ile polymorphism. RMD open. 2023 Academic Article GET IT
B Cell Reconstitution is Associated With COVID-19 Booster Vaccine Responsiveness in Patients Previously Seronegative Treated With Rituximab. The Journal of rheumatology. 2022 Academic Article GET IT
Times cited: 2
Chronic activation of pDCs in autoimmunity is linked to dysregulated ER stress and metabolic responses. The Journal of experimental medicine. 2022 Academic Article GET IT
Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission. Annals of the rheumatic diseases. 2022 Academic Article GET IT
Agreement Between Physician Evaluation and the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis. Arthritis care & research. 2022 Academic Article GET IT
Times cited: 1
New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension. Rheumatology (Oxford, England). 2022 Academic Article GET IT
Times cited: 29
Adipose-Derived Regenerative Cell Transplantation for the Treatment of Hand Dysfunction in Systemic Sclerosis: A Randomized Clinical Trial. Arthritis & rheumatology (Hoboken, N.J.). 2022 Academic Article GET IT
Mental Health Care Use and Associated Factors in Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Study. ACR open rheumatology. 2022 Academic Article GET IT
Rho Kinase Expression in Giant Cell Arteritis: Validating pERM Intensity Score to Increase Sensitivity of Temporal Artery Biopsy. The Journal of rheumatology. 2022 Academic Article GET IT
B Cell Reconstitution Is Strongly Associated With COVID-19 Vaccine Responsiveness in Rheumatic Disease Patients Who Received Treatment With Rituximab. Arthritis & rheumatology (Hoboken, N.J.). 2022 Academic Article GET IT
Times cited: 3
Prevalence of frailty in patients with polymyalgia rheumatica and association with health-related quality of life, cognition and sarcopenia. Rheumatology (Oxford, England). 2022 Academic Article GET IT
Circulating autoreactive proteinase 3+ B cells and tolerance checkpoints in ANCA-associated vasculitis. JCI insight. 2021 Academic Article GET IT
Serum Biomarkers of Disease Activity in Longitudinal Assessment of Patients with ANCA-Associated Vasculitis. ACR open rheumatology. 2021 Academic Article GET IT
Times cited: 10
A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale. Clinical and experimental rheumatology. 2021 Academic Article GET IT
Times cited: 3
Clinical Manifestations and Long-Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America. ACR open rheumatology. 2021 Academic Article GET IT
Times cited: 23
Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases. Annals of the rheumatic diseases. 2021 Letter GET IT
Times cited: 76
Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial. The Lancet. Rheumatology. 2021 Academic Article GET IT
Times cited: 62
Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial. Seminars in arthritis and rheumatism. 2021 Academic Article GET IT
Times cited: 7
Reply. Arthritis & rheumatology (Hoboken, N.J.). 2021 Letter GET IT
Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations. Arthritis research & therapy. 2021 Academic Article GET IT
Times cited: 43
Response to: 'Correspondence on 'Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement'' by Manetti. Annals of the rheumatic diseases. 2020 Comment GET IT
Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. ACR open rheumatology. 2020 Academic Article GET IT
Times cited: 66
Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement. Annals of the rheumatic diseases. 2020 Academic Article GET IT
Times cited: 17
Fc receptor-like 5 and anti-CD20 treatment response in granulomatosis with polyangiitis and microscopic polyangiitis. JCI insight. 2020 Academic Article GET IT
Times cited: 6
Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis. Frontiers in immunology. 2020 Academic Article GET IT
Times cited: 14
Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis. Arthritis & rheumatology (Hoboken, N.J.). 2020 Academic Article GET IT
Times cited: 78
Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Annals of the rheumatic diseases. 2020 Academic Article GET IT
Times cited: 112
Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis & rheumatology (Hoboken, N.J.). 2019 Academic Article GET IT
Times cited: 23
Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis & rheumatology (Hoboken, N.J.). 2019 Academic Article GET IT
Times cited: 23
Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Is There Still a Role for Cyclophosphamide?. Rheumatic diseases clinics of North America. 2019 Information Resource GET IT
The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis. Journal of autoimmunity. 2019 Academic Article GET IT
Times cited: 19
Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab. Arthritis & rheumatology (Hoboken, N.J.). 2019 Academic Article GET IT
Times cited: 77
Management of difficult polymyalgia rheumatica and giant cell arteritis: Updates for clinical practice. Best practice & research. Clinical rheumatology. 2019 Review GET IT
Physical or Occupational Therapy Use in Systemic Sclerosis: A Scleroderma Patient-centered Intervention Network Cohort Study. The Journal of rheumatology. 2019 Academic Article GET IT
Times cited: 4
Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I/II biomarker trial. Clinical and experimental rheumatology. 2018 Academic Article GET IT
Times cited: 26
The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. Rheumatology (Oxford, England). 2018 Academic Article GET IT
Times cited: 31
Arterial lesions in giant cell arteritis: A longitudinal study. Seminars in arthritis and rheumatism. 2018 Academic Article GET IT
Times cited: 44
Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis & rheumatology (Hoboken, N.J.). 2018 Academic Article GET IT
Times cited: 50
Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis. Rheumatology (Oxford, England). 2018 Academic Article GET IT
Times cited: 23
The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis. Clinical journal of the American Society of Nephrology : CJASN. 2018 Academic Article GET IT
Times cited: 54
Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8. Science translational medicine. 2018 Academic Article GET IT
Times cited: 81
Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: Results of a Randomized, Double-Blind, Placebo-Controlled, Pilot Trial. Arthritis & rheumatology (Hoboken, N.J.). 2017 Academic Article GET IT
Times cited: 105
Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis. American journal of nephrology. 2017 Academic Article GET IT
Times cited: 12
Inhibition of β-Catenin Signaling in the Skin Rescues Cutaneous Adipogenesis in Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial of C-82. The Journal of investigative dermatology. 2017 Academic Article GET IT
Times cited: 44
Trial of Tocilizumab in Giant-Cell Arteritis. The New England journal of medicine. 2017 Academic Article GET IT
Times cited: 596
Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis care & research. 2017 Academic Article GET IT
Times cited: 13
Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. Arthritis & rheumatology (Hoboken, N.J.). 2017 Academic Article GET IT
Times cited: 131
Proteomic Analysis of Sera from Individuals with Diffuse Cutaneous Systemic Sclerosis Reveals a Multianalyte Signature Associated with Clinical Improvement during Imatinib Mesylate Treatment. The Journal of rheumatology. 2017 Academic Article GET IT
Times cited: 19
A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Takayasu Arteritis. Arthritis & rheumatology (Hoboken, N.J.). 2017 Academic Article GET IT
Times cited: 140
A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis. Arthritis & rheumatology (Hoboken, N.J.). 2017 Academic Article GET IT
Times cited: 253
Integration of capillary microscopy and dermoscopy into the rheumatology fellow curriculum. Clinical and experimental rheumatology. 2017 Academic Article GET IT
Times cited: 4
Immunoglobulin (Ig)M antibodies to proteinase 3 in granulomatosis with polyangiitis and microscopic polyangiitis. Clinical and experimental immunology. 2017 Academic Article GET IT
Times cited: 7
Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis & rheumatology (Hoboken, N.J.). 2017 Academic Article GET IT
Times cited: 50
The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis & rheumatology (Hoboken, N.J.). 2017 Academic Article GET IT
Times cited: 15
A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. American journal of human genetics. 2016 Academic Article GET IT
Times cited: 74
Integrated, multicohort analysis of systemic sclerosis identifies robust transcriptional signature of disease severity. JCI insight. 2016 Academic Article GET IT
Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive and ANCA-Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets. Arthritis & rheumatology (Hoboken, N.J.). 2016 Academic Article GET IT
Times cited: 81
Comparison of change in end tidal carbon dioxide after three minutes of step exercise between systemic sclerosis patients with and without pulmonary hypertension. Rheumatology (Oxford, England). 2016 Academic Article GET IT
Times cited: 3
Dendritic cells maintain dermal adipose-derived stromal cells in skin fibrosis. The Journal of clinical investigation. 2016 Academic Article GET IT
Times cited: 40
Using Optimal Test Assembly Methods for Shortening Patient-Reported Outcome Measures: Development and Validation of the Cochin Hand Function Scale-6: A Scleroderma Patient-Centered Intervention Network Cohort Study. Arthritis care & research. 2016 Academic Article GET IT
Times cited: 11
Brief Report: A Prospective Open-Label Phase IIa Trial of Tocilizumab in the Treatment of Polymyalgia Rheumatica. Arthritis & rheumatology (Hoboken, N.J.). 2016 Academic Article GET IT
Times cited: 93
Examination of the association of sex and race/ethnicity with appearance concerns: a Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. Clinical and experimental rheumatology. 2016 Academic Article GET IT
Times cited: 5
Validation of the Self-Efficacy for Managing Chronic Disease Scale: A Scleroderma Patient-Centered Intervention Network Cohort Study. Arthritis care & research. 2016 Academic Article GET IT
Times cited: 17
Musculoskeletal Involvement in SSc Is Associated with Worse Scores on Short Form-36 and Scleroderma Health Assessment Questionnaire and Lower Tumor Necrosis Factor-α Gene Expression in Peripheral Blood Mononuclear Cells. HSS journal : the musculoskeletal journal of Hospital for Special Surgery. 2016 Academic Article GET IT
Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3. Arthritis & rheumatology (Hoboken, N.J.). 2016 Academic Article GET IT
Times cited: 131
The Recurrence of Digital Ulcers in Patients with Systemic Sclerosis after Discontinuation of Oral Treprostinil. The Journal of rheumatology. 2016 Academic Article GET IT
Times cited: 9
Using Mass Spectrometry to Quantify Rituximab and Perform Individualized Immunoglobulin Phenotyping in ANCA-Associated Vasculitis. Analytical chemistry. 2016 Academic Article GET IT
Times cited: 15
Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical Trials. JAMA. 2016 Academic Article GET IT
Times cited: 67
Stress granules and RNA processing bodies are novel autoantibody targets in systemic sclerosis. Arthritis research & therapy. 2016 Academic Article GET IT
Times cited: 14
B-cell-targeted therapy in systemic vasculitis. Current opinion in rheumatology. 2016 Information Resource GET IT
Times cited: 9
Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Annals of the rheumatic diseases. 2015 Academic Article GET IT
Times cited: 218
A longitudinal biomarker for the extent of skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis & rheumatology (Hoboken, N.J.). 2015 Academic Article GET IT
Times cited: 90
Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial. Arthritis research & therapy. 2015 Academic Article GET IT
Times cited: 68
Neutrophil-Related Gene Expression and Low-Density Granulocytes Associated With Disease Activity and Response to Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis & rheumatology (Hoboken, N.J.). 2015 Academic Article GET IT
Times cited: 118
Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. The Journal of clinical investigation. 2015 Academic Article GET IT
Times cited: 277
Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids. Arthritis & rheumatology (Hoboken, N.J.). 2015 Academic Article GET IT
Times cited: 40
A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility. American journal of human genetics. 2015 Academic Article GET IT
Times cited: 146
Pulmonary vasculitis. Rheumatic diseases clinics of North America. 2015 Information Resource GET IT
Times cited: 16
Peripheral CD5+ B cells in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis & rheumatology (Hoboken, N.J.). 2015 Academic Article GET IT
Times cited: 26
Current landscape of antineutrophil cytoplasmic antibody-associated vasculitis: classification, diagnosis, and treatment. Rheumatic diseases clinics of North America. 2015 Information Resource GET IT
Times cited: 16
Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. Journal of the American Society of Nephrology : JASN. 2014 Academic Article GET IT
Times cited: 134
Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis & rheumatology (Hoboken, N.J.). 2014 Academic Article GET IT
Times cited: 60
Increased rho kinase activity in temporal artery biopsies from patients with giant cell arteritis. Rheumatology (Oxford, England). 2014 Academic Article GET IT
Times cited: 15
Effectiveness of rituximab for the otolaryngologic manifestations of granulomatosis with polyangiitis (Wegener's). Arthritis care & research. 2014 Academic Article GET IT
Times cited: 14
Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial. Clinical and experimental rheumatology. 2014 Academic Article GET IT
Times cited: 23
Practice patterns of ANCA-associated vasculitis: exploring differences among subspecialties at a single academic medical centre. Clinical and experimental rheumatology. 2014 Academic Article GET IT
Times cited: 7
Brief report: The value of a patient global assessment of disease activity in granulomatosis with polyangiitis (Wegener's). Arthritis & rheumatology (Hoboken, N.J.). 2014 Academic Article GET IT
Times cited: 21
Submaximal heart and pulmonary evaluation: a novel noninvasive test to identify pulmonary hypertension in patients with systemic sclerosis. Arthritis care & research. 2013 Academic Article GET IT
Times cited: 5
Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis. Arthritis and rheumatism. 2013 Academic Article GET IT
Times cited: 135
Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis and rheumatism. 2013 Academic Article GET IT
Times cited: 100
Efficacy of remission-induction regimens for ANCA-associated vasculitis. The New England journal of medicine. 2013 Academic Article GET IT
Times cited: 597
Design of the tocilizumab in giant cell arteritis trial. International journal of rheumatology. 2013 Academic Article GET IT
Times cited: 108
Low prevalence of coeliac disease in patients with systemic sclerosis: a cross-sectional study of a registry cohort. Rheumatology (Oxford, England). 2013 Academic Article GET IT
Times cited: 19
Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis. Annals of the rheumatic diseases. 2012 Academic Article GET IT
Times cited: 111
Churg-strauss syndrome with eosinophilic myocarditis: a clinical pathology conference held by the division of rheumatology at hospital for special surgery. HSS journal : the musculoskeletal journal of Hospital for Special Surgery. 2012 Academic Article GET IT
Times cited: 5
Provisional diagnostic criteria for polymyalgia rheumatica: moving beyond clinical intuition?. Annals of the rheumatic diseases. 2012 Editorial Article GET IT
Times cited: 5
Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's). Arthritis care & research. 2012 Academic Article GET IT
Times cited: 51
Circulating angiopoietin-2 as a biomarker in ANCA-associated vasculitis. PloS one. 2012 Academic Article GET IT
Times cited: 15
IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis. Proceedings of the National Academy of Sciences of the United States of America. 2011 Academic Article GET IT
Times cited: 65
Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis and rheumatism. 2011 Academic Article GET IT
Times cited: 55
Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's). Arthritis care & research. 2011 Academic Article GET IT
Times cited: 67
Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort. Arthritis and rheumatism. 2011 Academic Article GET IT
Times cited: 62
A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. Arthritis care & research. 2011 Academic Article GET IT
Times cited: 145
Relationship between markers of platelet activation and inflammation with disease activity in Wegener's granulomatosis. The Journal of rheumatology. 2011 Academic Article GET IT
Times cited: 44
Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Annals of the rheumatic diseases. 2011 Academic Article GET IT
Times cited: 159
Alpha₁-antitrypsin deficiency-related alleles Z and S and the risk of Wegener's granulomatosis. Arthritis and rheumatism. 2010 Academic Article GET IT
Times cited: 85
Targeting tyrosine kinases: a novel therapeutic strategy for systemic sclerosis. Current opinion in rheumatology. 2010 Information Resource GET IT
Times cited: 17
Cyclophosphamide responsive interstitial lung disease in "overlap syndrome": a clinical pathology conference held by the division of rheumatology at the hospital for special surgery. HSS journal : the musculoskeletal journal of Hospital for Special Surgery. 2010 Academic Article GET IT
Rituximab versus cyclophosphamide for ANCA-associated vasculitis. The New England journal of medicine. 2010 Academic Article GET IT
Times cited: 2183
Glycosylation of proteinase 3 (PR3) is not required for its reactivity with antineutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis. Clinical and experimental rheumatology. 2009 Academic Article GET IT
Times cited: 6
Assessment of the item selection and weighting in the Birmingham vasculitis activity score for Wegener's granulomatosis. Arthritis and rheumatism. 2008 Academic Article GET IT
Times cited: 33
A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. Arthritis and rheumatism. 2008 Academic Article GET IT
Times cited: 94
Effects of glucocorticoids on weight change during the treatment of Wegener's granulomatosis. Arthritis and rheumatism. 2008 Academic Article GET IT
Times cited: 39
Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Annals of internal medicine. 2007 Academic Article GET IT
Times cited: 205
The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a thrombotic event. The Journal of rheumatology. 2007 Academic Article GET IT
Times cited: 43
ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. The American journal of medicine. 2007 Academic Article GET IT
Times cited: 187
Antiendothelial cell antibodies in patients with Wegener's granulomatosis: prevalence and correlation with disease activity and manifestations. The Journal of rheumatology. 2007 Academic Article GET IT
Times cited: 25
Therapy for giant cell arteritis: can we do better?. Arthritis and rheumatism. 2006 Editorial Article GET IT
Times cited: 13
Newer therapeutic approaches to the vasculitides: biologic agents. Rheumatic diseases clinics of North America. 2006 Information Resource GET IT
Times cited: 9
Herpes zoster in immunocompromised patients: incidence, timing, and risk factors. The American journal of medicine. 2005 Academic Article GET IT
Times cited: 56
Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and rheumatism. 2005 Academic Article GET IT
Times cited: 140
Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. Annals of internal medicine. 2005 Academic Article GET IT
Times cited: 232
A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis. Arthritis and rheumatism. 2005 Academic Article GET IT
Times cited: 36
Inflammatory disease in older adults. Cranial arteritis. Geriatrics. 2004 Information Resource GET IT
Times cited: 18
Domains of health-related quality of life important to patients with giant cell arteritis. Arthritis and rheumatism. 2003 Academic Article GET IT
Times cited: 27
Vision loss in giant cell arteritis patients treated with alternate-day corticosteroids: comment on the article by Hoffman et al. Arthritis and rheumatism. 2003 Letter GET IT
Times cited: 10
Long-term outcome in lupus nephritis. Annals of internal medicine. 2002 Letter GET IT
Times cited: 1
Methotrexate in giant-cell arteritis. Annals of internal medicine. 2001 Letter GET IT
A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clinical and experimental rheumatology. 2001 Academic Article GET IT
Times cited: 239
A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis and rheumatism. 2001 Academic Article GET IT
Times cited: 351
Visual performance in giant cell arteritis (temporal arteritis) after 1 year of therapy. The British journal of ophthalmology. 1999 Academic Article GET IT
Extramuscular manifestations in idiopathic inflammatory myopathies. Current opinion in rheumatology. 1998 Information Resource GET IT
Times cited: 38
Scleroderma in women with silicone breast implants: comment on the article by Sánchez-Guerrero et al. Arthritis and rheumatism. 1995 Letter GET IT
Times cited: 6
Breast implants and connective-tissue diseases. The New England journal of medicine. 1994 Article GET IT
Times cited: 10
Breast implants and connective-tissue diseases. The New England journal of medicine. 1994 Letter GET IT
Silicone breast implants and connective tissue disease. The Journal of rheumatology. 1994 Article GET IT
Times cited: 3
[The role of gastrectomy in the treatment of hemorrhaging stomach ulcers]. Zentralblatt fur Chirurgie. 1989 Academic Article GET IT
Excitatory amino acid antagonists depress acoustic startle after infusion into the ventral nucleus of the lateral lemniscus or paralemniscal zone. Brain research. 1988 Academic Article GET IT
Times cited: 25

VIVO Weill Cornell Medical College

Robert F Spiera Professor of Clinical Medicine

Publications

selected publications

Contact

full name

webpage

Phone

Publications

selected publications

Contact

full name

webpage